Dynavax (DVAX) MAA for HEPLISAV Accepted by EMA

Article Stock Quotes (1) Comments (0)

Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age and in patients with chronic kidney disease. Acceptance of the MAA confirms that the submission is sufficiently complete to permit a substantive review by the EMA.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
• VIVUS (VVUS) Reports Statistically Significant Data from STENDRA Study
• MediciNova (MNOV) Pops Higher Following Presentation of Significant MN-166 Phase Ib Data

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?